Study shows NeuroStar TMS (Neuronetics) successful for patients with Depression

New data show that the NeuroStar TMS Therapy System, from Neuronetics, induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD), which were maintained through one year of treatment. Clinical assessments were based on data obtained at three, six, nine and twelve months using the clinician-rated Clinical Global Impression Severity of Illness (CGI-S), and the patient-rated Patient Health Questionnaire (PHQ-9) and Inventory for Depressive Symptomatology-Self Report (IDS-SR).

At the end of acute treatment, 62% of patients achieved symptomatic improvement while 41% reported complete remission. At 12 months, 68% of patients achieved symptomatic improvement while 45% reported complete remission. Maintenance of benefit was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS reintroduction for symptom recurrence. The device was FDA approved in 2008 and in June 2012, Neuronetics received the CE Mark for the NeuroStar TMS. Data was presented at the annual meeting of the American Psychiatric Association.